Induced Pluripotent Stem Cell (iPSC) Market 2025

Induced Pluripotent Stem Cell (iPSC) Market Size

The global induced pluripotent stem cell (iPSC) market reached a value of nearly $1,961.76 million in 2024, having grown at a compound annual growth rate (CAGR) of 10.74% since 2019. The market is expected to grow from $1,961.76 million in 2024 to $3,099.47 million in 2029 at a rate of 9.58%. The market is then expected to grow at a CAGR of 8.87% from 2029 and reach $4,739.53 million in 2034. Growth in the historic period resulted from increasing healthcare expenditure, increase in the prevalence of chronic disorders, growing interest in personalized medicine, increasing prevalence of neurological disorders and rising prevalence of genetic disorders. Factors that negatively affected growth in the historic period were high associated costs and tumorigenicity risks. Going forward, rising number of clinical trials, growth in drug discovery and development, favorable government initiatives and growth in genomic projects will drive growth. Factor that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include were limited reimbursement coverage and lack of awareness on induced pluripotent stem cell.

Induced Pluripotent Stem Cell (iPSC) Market Drivers

The key drivers of the induced pluripotent stem cell (IPSC) market include: Rising Number Of Clinical Trials Rising number of clinical trials is expected to propel the growth of the induced pluripotent stem cell (iPSC) market going forward. iPSCs are increasingly used in disease modeling, toxicity screening, and regenerative therapies, leading to a surge in clinical trials—accelerating market adoption and validation. As clinical trials increase, more iPSC-based therapies are being tested for a range of conditions, enhancing their viability in regenerative and personalized medicine. Successful trials boost market confidence, encouraging both investors and healthcare providers to adopt iPSC solutions. iPSCs also improve disease models for drug discovery, reducing reliance on animal studies and accelerating the development process. These factors collectively drive the growing market for iPSC-based therapies and research tools. The rising number of clinical trials growth contribution during the forecast period in 2024 is 1.45%.

Induced Pluripotent Stem Cell (iPSC) Market Restraints

The key restraints on the induced pluripotent stem cell (IPSC) market include: Limited Reimbursement Coverage Limited reimbursement coverage is expected to hamper the growth of the induced pluripotent stem cell (iPSC) market. Lack of insurance coverage for stem cell-based therapies and diagnostics significantly limits patient access and commercial viability. The high cost of developing and producing iPSC-based therapies, including the expenses of generating iPSCs, maintaining cultures and performing advanced procedures, makes these treatments unaffordable for many patients without proper reimbursement coverage. Healthcare providers may be reluctant to adopt these therapies if they are not covered by insurance, slowing their market growth. Additionally, the lack of clear and consistent reimbursement policies creates uncertainty, hindering investment and delaying clinical trials, which ultimately delays the availability of iPSC-based therapies. Growth affected by limited reimbursement coverage during the forecast period in 2024 is -1.70%.

Induced Pluripotent Stem Cell (iPSC) Market Trends

Major trends shaping the induced pluripotent stem cell (IPSC) market include: Ready-To-Use iPSC Cell Lines Pave Way For Off-The-Shelf Cell Therapies Major companies operating in the induced pluripotent stem cell (iPSC) market are focusing on developing innovative ready-to-use, immune-cloaked iPSC cell lines to enhance the scalability and cost-effectiveness of cell therapies. These immune-cloaked cell lines are designed to evade immune rejection, facilitating their use in allogeneic therapies. By reducing the need for patient-specific cell preparation, these advancements aim to accelerate the development of off-the-shelf cell therapies for a broader range of conditions. For example, in February 2025, Cellistic, a US-based pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, launched Allo Chassis—ready-to-use, immune-cloaked iPSC cell lines derived from CD34+ (hematopoietic stem cells) and CD4+ (helper T-cell) primary cells. These cell lines are engineered using Cellistic’s proprietary STAR-CRISPR (CRISPR-based gene editing technology) to delete HLA class I and II antigens, minimizing immune rejection in allogeneic (donor-derived) therapies. Manufactured under current Good Manufacturing Practice (cGMP) standards, Allo Chassis offers therapeutic developers a cost-effective and time-efficient solution for creating product-specific master cell banks. The cell lines are available for immediate use and customization, streamlining the development of cell therapies for various applications, including regenerative medicine, immune-evasive CAR-T (Chimeric Antigen Receptor T-cell) and NK (Natural Killer) cell therapies, tissue engineering and organ transplantation. Innovative iPSC-Based Cancer Therapy Moves Forward With Significant Investment Major companies operating in the induced pluripotent stem cell (iPSC) market are strategically investing by focusing on the development of advanced cell culture systems and tools to improve iPSC generation, differentiation and characterization processes. They are actively working on optimizing production methods for higher efficiency and scalability, addressing challenges in regulatory compliance and developing new applications in drug discovery, regenerative medicine and disease modeling. For example, in August 2024, Shinobi Therapeutics, a US-based biotechnology company pioneering the development of off-the-shelf, immune-evasive cell therapies derived from induced pluripotent stem cells (iPSCs), secured a non-dilutive grant of up to $59 million from the Japanese Agency for Medical Research and Development (AMED) to advance its lead iPS-T cell therapy targeting GPC3-positive solid tumors. This funding will support the development of Shinobi's immune-evasive iPSC-derived T cell therapies, which aim to provide scalable, off-the-shelf treatments for cancer patients.

Opportunities And Recommendations In The Induced Pluripotent Stem Cell (iPSC) Market

Opportunities – The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by derived cell type will arise in the fibroblasts segment, which will gain $407.60 million of global annual sales by 2029. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by application will arise in the drug discovery and toxicity studies segment, which will gain $450.37 million of global annual sales by 2029. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by end-user will arise in the pharmaceutical and biotechnology companies segment, which will gain $543.74 million of global annual sales by 2029. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $395.50 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the induced pluripotent stem cell (iPSC) to focus on scaling allogeneic therapies with immune-cloaked iPSC lines, focus on advancing cell culture systems to improve iPSC efficiency and application, focus on standardized GMP-compliant iPSC lines to streamline development, focus on developing iPSC-derived BBB models to support CNS drug discovery, focus on hepatocytes to maximize growth opportunities, focus on regenerative medicine to drive long-term growth, expand in emerging markets, focus on strategic partnerships to accelerate iPSC development and commercialization, focus on competitive and value-based pricing to strengthen market position, focus on targeted outreach to key decision-makers in research and therapeutics, focus on strengthening digital channels to accelerate lead conversion and focus on academic and research institutes to capture highest growth.